Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2Classical hematology 2

Conditions

Anemia 4Primary Myelofibrosis 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2

Interventions

Cyclophosphamide 29fludarabine phosphate 27Mycophenolic Acid 21Peripheral Blood Stem Cell Transplantation 18Whole-Body Irradiation 17Cyclosporine 16Busulfan 15Tacrolimus 14Antilymphocyte Serum 12Melphalan 11Filgrastim 11fludarabine 10Cord Blood Stem Cell Transplantation 10Radiotherapy 7Methotrexate 7Methylprednisolone 6Etoposide 6Stem Cell Transplantation 4Cytarabine 4thymoglobulin 3Thiotepa 3Sirolimus 3Hematopoietic Stem Cell Transplantation 3Granulocyte Colony-Stimulating Factor 3Cyclosporins 3Alemtuzumab 3ruxolitinib 2luspatercept 2Specimen Handling 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Primary Myelofibrosis × luspatercept × Classical hematology × Clear all
NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Celgene

Phase 2 Completed
95 enrolled 32 charts
Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡